In a nutshell This study investigated the risk of pelvic fracture (PF) in patients with rectal cancer who received radiation therapy. Researchers suggested that there is an increased risk of PF in these patients. Some background Rectal cancer rates have been increasing, especially in younger populations. Due to improvements in medical care, survival...
Read MoreIn a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read More
In a nutshell This study investigated the use of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) to follow-up during treatment and predict the outcomes of patients with high-risk localized rectal cancer. Researchers suggested that this method can be very useful to assess the tumor before the surgery and predict response to...
Read More
In a nutshell This study investigated the effectiveness of first-line treatment with cetuximab (Erbitux) and bevacizumab (Avastin) in advanced colorectal cancer. Researchers suggested that cetuximab is associated with better outcomes when compared to bevacizumab. Some background Colorectal cancer is the third most common cancer worldwide....
Read MoreIn a nutshell This article reviewed the most common side effects of regorafenib (Stivarga) treatment for patients with metastatic (spread) colorectal cancer (mCRC). The author suggested methods to prevent these side effects to increase treatment adherence. Some background The standard treatment for mCRC is chemotherapy combined with...
Read MoreIn a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read More
In a nutshell This trial is examining the effectiveness and safety of encorafenib (Braftovi), binimetinib (Mektovi) and cetuximab (Erbitux) in patients with advanced colorectal cancer. The main outcome to be measured will be tumor response to the treatment. The details Colorectal cancer is the third most common cancer worldwide. A high number of...
Read More
In a nutshell This phase 2 trial is examining the effectiveness and safety of DS-8201a in the treatment of advanced HER2 positive colorectal cancer. The main outcome to be measured is the tumor response to the treatment and side effects. The details The standard treatment to advanced colorectal cancers is surgery, chemotherapy and radiation...
Read More
In a nutshell This phase 2 trial is examining the effectiveness and safety of durvalumab (Imfinzi) in the treatment of advanced rectal cancer that is not prone to genetic abnormalities. The main outcomes to be measured will be tumor response to the treatment and side effects. This trial is being conducted in the US. The details The standard treatment...
Read More
In a nutshell This study investigated whether statins (medication used to lower the cholesterol levels) improve survival of patients with rectal cancer. Researchers suggested that statins improved survival, particularly in older patients. Some background Colorectal cancer is the third most common cancer in the US. The standard treatment is...
Read More
In a nutshell This study compared the effectiveness of two different types of radiation therapy to treat rectal cancer. Researchers suggested that high-dose endorectal brachytherapy (HDEB) is associated with improved tumor response. Some background The standard treatment for rectal cancer that has spread outside the rectum lining (T3 tumor) is...
Read MoreIn a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for advanced or unresponsive colorectal cancer (CRC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...
Read More
